Press release

Evonik Health Care expands local presence in Thailand

Bangkok, Mach 29, 2017
  • Evonik establishes its first applied technology laboratory in Thailand 

  • New facility will support customers with the development of oral formulations for drug products and dietary supplements

  • Evonik’s office facility in Bangkok has been expanded to cater to the growing needs of businesses in the region


Evonik, one of the world’s leading specialty chemical companies, has opened a new applied technology laboratory in Bangkok, Thailand. This is the first laboratory in South East Asia for the Business Line Health Care. It is staffed and equipped to support customers with the development of oral formulations for drugs and dietary supplements.

The new facility is the latest addition to Evonik’s global network of Health Care laboratories. Dr. Stefan Randl, Vice President, Sales & Services at Evonik Health Care, Asia, explains: “South East Asia is an important growth region for Evonik Health Care. This new laboratory will allow us to work more closely with our customers on formulation solutions using our EUDRAGIT® and EUDRAGUARD®- functional polymer platforms. As local technical and regulatory requirements become more stringent, we felt it was timely to invest to strengthen our customer support in the region.”

EUDRAGIT® polymers have outstanding protective, enteric and sustained-release properties. They are the pharmaceutical industry’s preferred solution for targeted drug release of solid oral dosage forms. EUDRAGUARD® is a broad toolkit of polymers which has been specifically developed for the nutraceutical industry. It is used to coat dietary supplements for targeted delivery, improved uptake in the body, and better bioavailability.

The applied technology laboratory is equipped with a drum coater and fluidized bed for drying, granulation and coating. In addition, it has analytical capabilities, for example to conduct drug release tests. These resources enable Evonik to train customers and partners on the use of its polymer excipients, to develop oral formulations and to provide production support.

The new applied technology laboratory resides within Evonik’s expanded office facilities located in Bangkok’s Exchange Tower. “After being active in Thailand for more than 30 years, our newly expanded office premises in Bangkok will allow us to further grow and enhance our presence in the country,” remarked Peter Meinshausen, Regional President of Evonik South East Asia, Australia and New Zealand. “In light of this development, and the newly established Health Care laboratory, I am very much looking forward to continuing to build on our momentum in this dynamic and prosperous region.”

Linked Files

Download
Download
Contact

Hannah Rausche

Head of Communications Health Care

Janna Schneidewindt

Head of Regional Communication South East Asia, Australia & NZ

  • Company information

    Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world with more than 35,000 employees. In fiscal 2016 the enterprise generated sales of around €12,7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.

  • About Nutrition & Care

    The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,500 employees, and generated sales of around €4.3 billion in 2016.

  • Disclaimer

    In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.